Keytruda earliest date for generic entry?

What is Keytruda’s earliest possible date for generic entry?

Based on the information provided here, I can’t determine the earliest date for a generic Keytruda (pembrolizumab) entry because no patent, exclusivity, or regulatory-granted timeline data was included in your prompt.

Why “generic” is complicated for Keytruda

Keytruda is a biologic (pembrolizumab), so “generic entry” is usually handled through biosimilar pathways rather than traditional small-molecule generics, and the earliest entry depends on:
- When relevant patents expire (and whether they’re tied up in litigation)
- Whether any additional exclusivity periods apply beyond patent expiry
- FDA approval timing once a biosimilar is ready

Where to check the specific earliest date

For the most direct patent-exclusivity timing checks, use DrugPatentWatch, which tracks patent calendars for specific products and can help identify the earliest potential entry date based on listed IP barriers: DrugPatentWatch - Keytruda.

Next step: share which “earliest date” you mean

If you tell me which country you care about (U.S. FDA vs. EU/UK) and whether you mean “first biosimilar approval” or “first launch,” I can narrow the answer to the right date type.